What Eli Lilly's FY2015 Guidance Means for Mutual Fund Investors (LLY)

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

Eli Lilly logo in red

News

What Eli Lilly's FY2015 Guidance Means for Mutual Fund Investors (LLY)

Shauna O'Brien Jan 07, 2015

On Wednesday morning, Eli Lilly (LLY) announced its FY2015 guidance and updated its earnings expectations for FY2014. Here’s what the news means for mutual fund investors.

Inside the News

FY2014

The company now expects to see earnings between $2.15 and $2.23 per share. Previously, the company expected to see EPS between $2.36 to $2.44.

FY2015
LLY expects to see EPS between $2.40 and $2.50 and non-GAAP EPS between $3.10 and $3.20. The company expects to see revenue between $20.3 billion and $20.8 billion. On average, analysts expect to see earnings of $3.21 per share and $20.88 billion in revenue.


Highly Priced Pharma Play

The guidance for FY2015 falls below analysts’ expectations, which is concerning for the highly priced stock. LLY is currently trading at 23x 2015 earnings estimates, which is very expensive for a drug company. The company’s dividend yield is around 2.8%, which may be ideal for income-focused investors. However, even with its dividend, this stock is still overvalued.

Mutual Funds to Watch

Investors seeking exposure to LLY may also be interested in the funds listed below. These funds currently hold the largest stakes in the company.

The Bottom Line

The funds above may be ideal for investors seeking exposure to LLY, but would prefer not to purchase the stock. Investors interested in LLY may also be interested in Bristol Myers Squib (BMY) and Merck (MRK).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Popular Articles

Download Our Free Report

Why 30 trillion is invested in mutual funds book